Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
Date:4/21/2011

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss first quarter 2011 financial results, as well as provide a general business overview on Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 p.m. Central European Time).  Financial results for the first quarter ended March 31, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/investors/event-calendarWithin the U.S.:

888-771-4371International:

847-585-4405Passcode:

29609004#A replay of the presentation will be available on the Onyx website or by dialing:Dial in:

630-652-3042 Passcode:

29609004# (approximately one hour after the teleconference concludes)  The replay will be available through May 18, 2011. About Onyx Pharmaceuticals, Inc.Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
2. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
3. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
4. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
8. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
9. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
10. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
11. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... N.C., June 20, 2011 Pharmaceutical Institute, the ... pharmaceutical and biotech industry and a subsidiary of ... updates to its Therapeutic Area Essentials™ ... disease state training for pharmaceutical and biotech R&D ...
... dreamed of becoming a pilot for as long as he can ... child opting to play with toy planes instead of cars, and ... a family trip to Disney World.  At 8-years old Baniecki scribbled ... airline pilot and placed it into a time capsule.  Ten years ...
Cached Medicine Technology:Therapeutic Area Essentials "Class of 2011" Brings Current Disease State Training to Pharma 2Pilot's Dream Comes True Thanks to New Robotic Surgery 2Pilot's Dream Comes True Thanks to New Robotic Surgery 3Pilot's Dream Comes True Thanks to New Robotic Surgery 4
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle ... 15 seconds of unique footage that users can shrink and stretch in the Final ... more. Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... the company to freely market and sell Arterosil and Arterosil HP, and that ... Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... with profound hearing disabilities and President A.P.J.Abdul Kalam today ... to intensify their drive to reduce the number of ... the 3rd Cochlear Implant Group of India Conference in ... with severe hearing disability, 0.9 million people with moderate ...
... has been found to have less side effects and ... the allergen is given as a vaccine in order ... antibodies which are already present helps to counteract the ... injections against allergy diseases such as hay fever, cat ...
... leader Colgate-Palmolive Company has entered into an alliance with ... designed to fight against pre-cancerous //conditions in the oral ... this end Colgate purchased $20 million of Introgen shares ... by Introgen. Introgen has a wide range of molecular ...
... November issue of the Journal of the National Cancer Institute, ... treatment, and patients treated with the higher chemotherapy dose had ... testicular cancer is the most common cancer among 20-40 year ... age at which they are starting a family, and the ...
... that rheumatoid arthritis patients respond differently to the same ... new study now explains that it is due to ... following experiments conducted on animal models of mouse that ... such complex behaviors could enable physicians make an individualized ...
... FDA approved long-term treatment regime for patients with treatment ... now being offered to patients at NewYork-Presbyterian Hospital/Columbia University ... first treatment specifically approved for TRD in patients over ... been unsuccessful atleast in four or more of the ...
Cached Medicine News:Health News:Kalam Appeals to Eradicate Hearing Disability 2Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:Study Offers Insights Into Treatment Of Rheumatoid Arthritis 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: